Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 6;7(11):1350–1373. doi: 10.1038/s41551-023-01061-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 5 — a, Schematic representation of the injection of AAV9 vectors to the RVLM. Micrographic image is representative of three rats analysed in Fig. 3b. GFP-derived fluorescence indicates cells expressing the transgene. Scale bar, 1 mm. b,c, Efficiency and specificity of astrocyte-specific expression of the transgene. (b) Micrographic images of GFP (green) and anti-NeuN immunostaining for mature neurons (blue) of the RVLM of SHRSPs analysed in Fig. 3b. Scale bar, 50 μm. Images are representative of three rats. (c) Relative populations (%) of GFP/ GFAP/ double positive (GFP⁺ GFAP⁺) or GFP/ NeuN/ double positive (GFP⁺ NeuN⁺) cells were calculated by referring their numbers to those of GFP⁺, GFAP⁺ or NeuN⁺ cells (n = 3 rats for each group). d,e, Efficiency and specificity of neuron-specific expression of the transgene. (d) Micrographic images of GFP (green) and anti-GFAP immunostaining (blue) of the RVLM of SHRSPs analysed in Fig. 3c. Scale bar, 50 μm. Images are representative of three rats. (e) Efficiency and specificity quantified as in (c). f, MAP in SHRSPs injected with the control vectors. Blood pressure was measured and MAP was quantified as in Fig. 1b (n = 6 rats for GFAP-control; n = 7 rats for NSE-control). The data for blue line are identical to those demonstrated with blue line in Extended Data Fig. 1a. g, Four-week time courses of MAP. The experimental protocol was identical to that for Fig. 3 except for the observation period after the AAV injection. The data for Day 1 and Day 15 are identical to those for GFAP-control and GFAP-AGTRAP shown in Fig. 3d,e (GFAP-control: n = 6 rats for Day 1, Day 8, and Day 15; n = 3 rats for Day 22 and Day 29. GFAP-AGTRAP: n = 7 rats for Day 1, Day 8, and Day 15; n = 3 rats for Day 22 and Day 29). Data are presented as mean ± s.e.m. *P < 0.05; ***P < 0.001; NS, not significant; unpaired two-tailed Student’s t-test (c,e) and two-way repeated measures ANOVA with Tukey’s (f) or Bonferroni’s (g) post hoc multiple comparisons test. Details of statistical analyses are provided in Supplementary Information.

Source data